The effect of tofacitinib on residual pain in patients with psoriatic arthritis

The effect of tofacitinib on residual pain in patients with psoriatic arthritis

Bibliographic Details
Main Authors:	Dougados, M, van der Heijde, D, Bingham, CO, Taylor, PC, Fallon, L, Woolcott, J, Brault, Y, Wang, L, Kessouri, M
Format:	Conference item
Language:	English
Published:	BMJ Publishing Group 2020

Similar Items

The effect of tofacitinib on residual pain in patients with rheumatoid arthritis and psoriatic arthritis
by: Dougados, M, et al.
Published: (2022)

The effect of tofacitinib on residual pain in patients with rheumatoid arthritis and psoriatic arthritis
by: Maxime Dougados, et al.
Published: (2022-11-01)

Median time to pain improvement in patients with psoriatic arthritis treated with tofacitinib
by: de Vlam, K, et al.
Published: (2018)

Median time to pain improvement and the impact of baseline pain severity on pain response in patients with psoriatic arthritis treated with tofacitinib
by: de Vlam, K, et al.
Published: (2021)

Understanding mediators of pain reduction in psoriatic arthritis patients treated with tofacitinib: role of inflammation
by: Taylor, P, et al.
Published: (2019)

Baseline pain severity as a predictor of pain improvement following treatment with tofacitinib in psoriatic arthritis
by: Ogdie, A, et al.
Published: (2018)

Identifying and quantifying the role of inflammation in pain reduction for patients with psoriatic arthritis treated with tofacitinib: a mediation analysis
by: de Vlam, K, et al.
Published: (2022)

Identifying mediators of pain reduction in patients with psoriatic arthritis treated with tofacitinib: Role of inflammation associated with peripheral arthritis, enthesitis and skin disease
by: Taylor, PC, et al.
Published: (2020)

Effectiveness of Tofacitinib in Patients Initiating Therapy for Psoriatic Arthritis: Results from the CorEvitas Psoriatic Arthritis/Spondyloarthritis Registry
by: Philip J. Mease, et al.
Published: (2024-01-01)

Post-marketing safety surveillance of tofacitinib over 9 years in patients with psoriatic arthritis and rheumatoid arthritis
by: Burmester, GR, et al.
Published: (2023)

Influenza Adverse Events in Patients with Rheumatoid Arthritis, Ulcerative Colitis, or Psoriatic Arthritis in the Tofacitinib Clinical Development Programs
by: Kevin L. Winthrop, et al.
Published: (2022-12-01)

Tofacitinib improves composite endpoint measures of disease in patients with psoriatic arthritis
by: Helliwell, P, et al.
Published: (2018)

EFFICACY AND SAFETY OF TOFACITINIB IN PATIENTS WITH PSORIATIC ARTHRITIS IN REAL CLINICAL PRACTICE
by: E. Yu. Loginova, et al.
Published: (2020-06-01)

Pain reduction in patients with rheumatoid arthritis receiving tofacitinib monotherapy with or without pain medication: A post hoc analysis of pooled data from phase 2, phase 3 and phase 3B/4 studies
by: Taylor, PC, et al.
Published: (2019)

Tofacitinib in the management of active psoriatic arthritis: patient selection and perspectives
by: Ly K, et al.
Published: (2019-08-01)

Effect of tofacitinib treatment on active MRI sacroiliitis in psoriatic arthritis patients
by: E. E. Gubar, et al.
Published: (2021-05-01)

Post-Marketing Safety Surveillance of Tofacitinib over 9 Years in Patients with Psoriatic Arthritis and Rheumatoid Arthritis
by: Gerd R. Burmester, et al.
Published: (2023-07-01)

Time to response for clinical and patient-reported outcomes in patients with psoriatic arthritis treated with tofacitinib, adalimumab, or placebo
by: Gladman, DD, et al.
Published: (2022)

Itch as major mediator of effect of tofacitinib on health-related quality of life in psoriatic arthritis: a mediation analysis
by: Taylor, PC, et al.
Published: (2021)

Correction: Post-Marketing Safety Surveillance of Tofacitinib over 9 Years in Patients with Psoriatic Arthritis and Rheumatoid Arthritis
by: Gerd R. Burmester, et al.
Published: (2023-12-01)

Results of studying the clinical efficacy and safety of tofacitinib in the treatment of psoriatic arthritis
by: T. V. Korotaeva, et al.
Published: (2019-05-01)

Relationships between psoriatic arthritis composite measures of disease activity with patient-reported outcomes in Phase 3 studies of tofacitinib
by: Coates, L, et al.
Published: (2021)

Comparative efficacy of tofacitinib and adalimumab in patients with psoriatic arthritis in real clinical practice. Data from the Russian nationwide register of patients with psoriatic arthritis
by: E. Yu. Loginova, et al.
Published: (2021-06-01)

Time to response for clinical and patient-reported outcomes in patients with psoriatic arthritis treated with tofacitinib, adalimumab, or placebo
by: Dafna D. Gladman, et al.
Published: (2022-02-01)

Efficacy of tofacitinib for the treatment of psoriatic arthritis: pooled analysis of two phase 3 studies
by: Nash, P, et al.
Published: (2018)

Pharmacokinetic boosting to enable a once-daily reduced dose of tofacitinib in patients with rheumatoid arthritis and psoriatic arthritis (the PRACTICAL study)
by: Céleste J.T. van der Togt, et al.
Published: (2022-12-01)

Tofacitinib as monotherapy following methotrexate withdrawal in patients with psoriatic arthritis previously treated with open-label tofacitinib plus methotrexate: a randomised, placebo-controlled substudy of OPAL Balance
by: Nash, P, et al.
Published: (2020)

Efficacy of Tofacitinib for the Treatment of Psoriatic Arthritis: Pooled Analysis of Two Phase 3 Studies
by: Peter Nash, et al.
Published: (2018-11-01)

Impact of tofacitinib on patient-reported outcomes in patients with psoriatic arthritis. Data from the real clinical practice
by: L. D. Vorobyeva, et al.
Published: (2022-07-01)

New GRAPPA and EULAR recommendations for the management of psoriatic arthritis
by: Coates, L, et al.
Published: (2017)

Relationships of dermatologic symptoms and quality of life in patients with psoriatic arthritis: analysis of two tofacitinib phase III studies
by: Taylor, P, et al.
Published: (2022)

Itch as Major Mediator of Effect of Tofacitinib on Health-Related Quality of Life in Psoriatic Arthritis: A Mediation Analysis
by: Peter C. Taylor, et al.
Published: (2021-09-01)

Relationships of dermatologic symptoms and quality of life in patients with psoriatic arthritis: analysis of two tofacitinib phase III studies
by: Peter C. Taylor, et al.
Published: (2022-07-01)

Safety and efficacy of tofacitinib up to 48 months in patients with active psoriatic arthritis: final analysis of the OPAL Balance long-term extension study
by: Nash, P, et al.
Published: (2021)

Network Meta-Analysis of Tofacitinib, Biologic Disease-Modifying Antirheumatic Drugs, and Apremilast for the Treatment of Psoriatic Arthritis
by: Dafna D. Gladman, MD, et al.
Published: (2020-01-01)

Association between baseline cardiovascular risk and incidence rates of major adverse cardiovascular events and malignancies in patients with psoriatic arthritis and psoriasis receiving tofacitinib
by: Lars E. Kristensen, et al.
Published: (2023-02-01)

Persistence of Tofacitinib in the Treatment of Rheumatoid Arthritis in Open‐Label, Long‐Term Extension Studies up to 9.5 Years
by: Janet E. Pope, et al.
Published: (2019-04-01)

Patient perception of medical care for psoriatic arthritis in North America and Europe: results from a global patient survey
by: Richette, P, et al.
Published: (2022)

Assessing structural damage progression in psoriatic arthritis and its role as an outcome in research
by: Désirée van der Heijde, et al.
Published: (2020-02-01)

Efficacy of tofacitinib on enthesitis in patients with active psoriatic arthritis: analysis of pooled data from two phase 3 studies
by: Philip J. Mease, et al.
Published: (2023-08-01)